ELAN Stock Overview
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ELAN from our risk checks.
My Notes
NewNotes are coming soon
Elanco Animal Health Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.79 |
| 52 Week High | US$29.66 |
| 52 Week Low | US$11.18 |
| Beta | 0.93 |
| 1 Month Change | 8.58% |
| 3 Month Change | 14.34% |
| 1 Year Change | -44.53% |
| 3 Year Change | -56.57% |
| 5 Year Change | n/a |
| Change since IPO | -61.69% |
Recent News & Updates
Recent updates
Elanco's Tangible Equity Units: Living With The Worst Case
Dec 13We Think Elanco Animal Health (NYSE:ELAN) Is Taking Some Risk With Its Debt
Nov 08
Elanco Q3 2022 Earnings Preview
Nov 07Elanco Animal Health: This 'Sick Dog' Should Recover
Oct 19Elanco adds 9% as activist investor Sachem Head raises stake
Sep 09Elanco Animal Health hits another 52-week low. What's going on with the company?
Aug 23Elanco Animal Health hits 52-week low; down 33% YTD
Aug 16Elanco Q2 2022 Earnings Preview
Aug 05We Think Elanco Animal Health (NYSE:ELAN) Is Taking Some Risk With Its Debt
Jul 25Elanco Animal Health: Bullish Beyond Near-Term 'Bird Flu' Headwinds
Apr 19Is Elanco Animal Health (NYSE:ELAN) A Risky Investment?
Apr 13Elanco Animal Health: Getting Healthier, Slowly
Feb 02We Think Elanco Animal Health (NYSE:ELAN) Is Taking Some Risk With Its Debt
Jan 10An Intrinsic Calculation For Elanco Animal Health Incorporated (NYSE:ELAN) Suggests It's 29% Undervalued
Sep 09Elanco's Tangible Equity Units: Low-Risk Option With A 5% Yield
Aug 21Does Elanco Animal Health (NYSE:ELAN) Have A Healthy Balance Sheet?
Jun 20TriRx Pharma to acquire Elanco Animal's two facilities in Kansas and U.K.
Jun 15An Intrinsic Calculation For Elanco Animal Health Incorporated (NYSE:ELAN) Suggests It's 40% Undervalued
May 12Elanco Q1 2021 Earnings Preview
May 06Elanco Animal Health (NYSE:ELAN) Seems To Be Using A Lot Of Debt
Mar 21Need To Know: Elanco Animal Health Incorporated (NYSE:ELAN) Insiders Have Been Buying Shares
Feb 23Elanco Animal Health: Investor Day Highlights Path Toward Closing The Valuation Gap
Jan 03Elanco Animal Health Incorporated's (NYSE:ELAN) Intrinsic Value Is Potentially 65% Above Its Share Price
Jan 01Elanco Animal Health (ELAN) Investor Presentation - Slideshow
Dec 16Elanco upgrades revenue guidance; shares jump 6%
Dec 15Elanco buys rights to KindredBio's canine parvovirus therapy
Dec 11Elanco announces public offering of common stock by selling shareholder
Nov 30Shareholder Returns
| ELAN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.4% | -0.7% | 0.9% |
| 1Y | -44.5% | 4.9% | -10.9% |
Return vs Industry: ELAN underperformed the US Pharmaceuticals industry which returned 4.6% over the past year.
Return vs Market: ELAN underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| ELAN volatility | |
|---|---|
| ELAN Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ELAN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ELAN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 9,000 | Jeff Simmons | https://www.elanco.com |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations.
Elanco Animal Health Incorporated Fundamentals Summary
| ELAN fundamental statistics | |
|---|---|
| Market Cap | US$6.54b |
| Earnings (TTM) | -US$120.00m |
| Revenue (TTM) | US$4.54b |
1.4x
P/S Ratio-54.5x
P/E RatioIs ELAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELAN income statement (TTM) | |
|---|---|
| Revenue | US$4.54b |
| Cost of Revenue | US$1.91b |
| Gross Profit | US$2.63b |
| Other Expenses | US$2.75b |
| Earnings | -US$120.00m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 21, 2023
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 57.89% |
| Net Profit Margin | -2.64% |
| Debt/Equity Ratio | 87.5% |
How did ELAN perform over the long term?
See historical performance and comparison